346 related articles for article (PubMed ID: 25019993)
1. Epigenetic regulation leading to induced pluripotency drives cancer development in vivo.
Ohnishi K; Semi K; Yamada Y
Biochem Biophys Res Commun; 2014 Dec; 455(1-2):10-5. PubMed ID: 25019993
[TBL] [Abstract][Full Text] [Related]
2. Premature termination of reprogramming in vivo leads to cancer development through altered epigenetic regulation.
Ohnishi K; Semi K; Yamamoto T; Shimizu M; Tanaka A; Mitsunaga K; Okita K; Osafune K; Arioka Y; Maeda T; Soejima H; Moriwaki H; Yamanaka S; Woltjen K; Yamada Y
Cell; 2014 Feb; 156(4):663-77. PubMed ID: 24529372
[TBL] [Abstract][Full Text] [Related]
3. [Application of reprogramming technology for cancer research].
Yagi M; Semi K; Yamada Y
Nihon Rinsho; 2015 May; 73(5):751-5. PubMed ID: 25985626
[TBL] [Abstract][Full Text] [Related]
4. Transcriptional and epigenetic mechanisms of cellular reprogramming to induced pluripotency.
van den Hurk M; Kenis G; Bardy C; van den Hove DL; Gage FH; Steinbusch HW; Rutten BP
Epigenomics; 2016 Aug; 8(8):1131-49. PubMed ID: 27419933
[TBL] [Abstract][Full Text] [Related]
5. Induced pluripotent stem cell technology for dissecting the cancer epigenome.
Semi K; Yamada Y
Cancer Sci; 2015 Oct; 106(10):1251-6. PubMed ID: 26224327
[TBL] [Abstract][Full Text] [Related]
6. The Epigenetic Reprogramming Roadmap in Generation of iPSCs from Somatic Cells.
Brix J; Zhou Y; Luo Y
J Genet Genomics; 2015 Dec; 42(12):661-70. PubMed ID: 26743984
[TBL] [Abstract][Full Text] [Related]
7. Reprogramming cancer cells: a novel approach for cancer therapy or a tool for disease-modeling?
Yilmazer A; de Lázaro I; Taheri H
Cancer Lett; 2015 Dec; 369(1):1-8. PubMed ID: 26276716
[TBL] [Abstract][Full Text] [Related]
8. Application of iPS cell technology to cancer epigenome study: uncovering the mechanism of cell status conversion for drug resistance in tumor.
Matsuda Y; Semi K; Yamada Y
Pathol Int; 2014 Jul; 64(7):299-308. PubMed ID: 25047500
[TBL] [Abstract][Full Text] [Related]
9. Global epigenetic changes during somatic cell reprogramming to iPS cells.
Mattout A; Biran A; Meshorer E
J Mol Cell Biol; 2011 Dec; 3(6):341-50. PubMed ID: 22044880
[TBL] [Abstract][Full Text] [Related]
10. Integration-free reprogramming of human somatic cells to induced pluripotent stem cells (iPSCs) without viral vectors, recombinant DNA, and genetic modification.
Heng BC; Fussenegger M
Methods Mol Biol; 2014; 1151():75-94. PubMed ID: 24838880
[TBL] [Abstract][Full Text] [Related]
11. Conversion of genomic imprinting by reprogramming and redifferentiation.
Kim MJ; Choi HW; Jang HJ; Chung HM; Arauzo-Bravo MJ; Schöler HR; Do JT
J Cell Sci; 2013 Jun; 126(Pt 11):2516-24. PubMed ID: 23525019
[TBL] [Abstract][Full Text] [Related]
12. Cellular reprogramming and cancer development.
Semi K; Matsuda Y; Ohnishi K; Yamada Y
Int J Cancer; 2013 Mar; 132(6):1240-8. PubMed ID: 23180619
[TBL] [Abstract][Full Text] [Related]
13. The causal relationship between epigenetic abnormality and cancer development: in vivo reprogramming and its future application.
Yamada Y; Yamada Y
Proc Jpn Acad Ser B Phys Biol Sci; 2018; 94(6):235-247. PubMed ID: 29887568
[TBL] [Abstract][Full Text] [Related]
14. TRIM28 epigenetic corepressor is indispensable for stable induced pluripotent stem cell formation.
Klimczak M; Czerwińska P; Mazurek S; Sozańska B; Biecek P; Mackiewicz A; Wiznerowicz M
Stem Cell Res; 2017 Aug; 23():163-172. PubMed ID: 28759843
[TBL] [Abstract][Full Text] [Related]
15. Concise review: Induced pluripotent stem cells versus embryonic stem cells: close enough or yet too far apart?
Bilic J; Izpisua Belmonte JC
Stem Cells; 2012 Jan; 30(1):33-41. PubMed ID: 22213481
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic modifications in the embryonic and induced pluripotent stem cells.
Godini R; Lafta HY; Fallahi H
Gene Expr Patterns; 2018 Sep; 29():1-9. PubMed ID: 29625185
[TBL] [Abstract][Full Text] [Related]
17. Increased reprogramming capacity of mouse liver progenitor cells, compared with differentiated liver cells, requires the BAF complex.
Kleger A; Mahaddalkar PU; Katz SF; Lechel A; Joo JY; Loya K; Lin Q; Hartmann D; Liebau S; Kraus JM; Cantz T; Kestler HA; Zaehres H; Schöler H; Rudolph KL
Gastroenterology; 2012 Apr; 142(4):907-17. PubMed ID: 22245845
[TBL] [Abstract][Full Text] [Related]
18. Environmental epigenetic modifications and reprogramming-recalcitrant genes.
Sakurada K
Stem Cell Res; 2010 May; 4(3):157-64. PubMed ID: 20167552
[TBL] [Abstract][Full Text] [Related]
19. Induced pluripotent stem cells reprogramming: Epigenetics and applications in the regenerative medicine.
Gomes KM; Costa IC; Santos JF; Dourado PM; Forni MF; Ferreira JC
Rev Assoc Med Bras (1992); 2017 Feb; 63(2):180-189. PubMed ID: 28355380
[TBL] [Abstract][Full Text] [Related]
20. Current status in cancer cell reprogramming and its clinical implications.
Izgi K; Canatan H; Iskender B
J Cancer Res Clin Oncol; 2017 Mar; 143(3):371-383. PubMed ID: 27620745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
